中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.021 seconds)

    Tubulin isotype screening in cancer therapy using halichondrin B analogs
    3.
    发明申请
    Tubulin isotype screening in cancer therapy using halichondrin B analogs 审中-公开
    使用软骨素B类似物的癌症治疗中的微管蛋白同种型筛选

    公开(公告)号：US20060154312A1

    公开(公告)日：2006-07-13

    申请号：US11299260

    申请日：2005-12-07

    Applicant: Sergei Agoulnik ,  Galina Kuznetsov ,  Bruce Littlefield

    Inventor： Sergei Agoulnik ,  Galina Kuznetsov ,  Bruce Littlefield

    IPC: G01N33/574 ,  A61K31/353

    CPC classification number: A61K31/353 ,  G01N33/5091 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/57496 ,  G01N2500/00 ,  Y10T436/143333

    Abstract: Chemotherapeutic agents that interfere with microtubule assembly or disassembly in the cell are potent inhibitors of cell replication. Examples of such agents include halichondrin B analogs. It has been shown that the susceptibility of certain cancers to analogs of halichondrin B correlates with the expression of particular tubulin isotypes or other microtubule-associated proteins such as MAP-4 and stathmin. Correlations such as these may be used in identifying patients suitable for treatment using a particular chemotherapeutic agent. Such a system avoids treating patients with cytotoxic compounds where there is a minimal or no effect on the cancer. The invention also provides a system of establishing these correlations for different compounds and cancer types. The system will be particularly useful in establishing correlations between anti-microtubule agents and cancers such as lung, breast, and ovarian cancer. Kits and reagents useful in practicing the invention are also provided.

    Abstract translation: 影响细胞中微管组装或分解的化学治疗剂是细胞复制的有效抑制剂。 这些试剂的实例包括软骨素B类似物。 已经显示某些癌症对软骨素B类似物的易感性与特定的微管蛋白同种型或其它微管相关蛋白如MAP-4和stathmin的表达相关。 诸如这些的相关性可以用于鉴定适合于使用特定化学治疗剂的治疗的患者。 这样的系统避免了治疗患有细胞毒性化合物的患者，其中对癌症最小或没有影响。 本发明还提供了一种为不同化合物和癌症类型建立这些相关性的系统。 该系统将特别有用于建立抗微管剂和肺癌，乳腺癌和卵巢癌等癌症之间的相关性。 还提供了可用于实践本发明的试剂盒和试剂。

    Tubulin Isotype Screening in Cancer Therapy Using Halichondrin B Analogs
    8.
    发明申请
    Tubulin Isotype Screening in Cancer Therapy Using Halichondrin B Analogs 审中-公开
    使用Halichondrin B类似物的癌症治疗中的微管蛋白同种型筛选

    公开(公告)号：US20100190843A1

    公开(公告)日：2010-07-29

    申请号：US12534277

    申请日：2009-08-03

    Applicant: Sergei Agoulnik ,  Galina Kuznetsov ,  Bruce A. Littlefield

    Inventor： Sergei Agoulnik ,  Galina Kuznetsov ,  Bruce A. Littlefield

    IPC: A61K31/335 ,  C07H21/04 ,  G01N33/68 ,  C12Q1/02 ,  G01N33/48 ,  C12Q1/68 ,  C40B30/04 ,  G01N33/53 ,  A61P35/00

    CPC classification number: A61K31/353 ,  G01N33/5091 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/57496 ,  G01N2500/00 ,  Y10T436/143333

    Abstract: Chemotherapeutic agents that interfere with microtubule assembly or disassembly in the cell are potent inhibitors of cell replication. Examples of such agents include halichondrin B analogs. It has been shown that the susceptibility of certain cancers to analogs of halichondrin B correlates with the expression of particular tubulin isotypes or other microtubule-associated proteins such as MAP-4 and stathmin. Correlations such as these may be used in identifying patients suitable for treatment using a particular chemotherapeutic agent. Such a system avoids treating patients with cytotoxic compounds where there is a minimal or no effect on the cancer. The invention also provides a system of establishing these correlations for different compounds and cancer types. The system will be particularly useful in establishing correlations between anti-microtubule agents and cancers such as lung, breast, and ovarian cancer. Kits and reagents useful in practicing the invention are also provided.

    Abstract translation: 影响细胞中微管组装或分解的化学治疗剂是细胞复制的有效抑制剂。 这些试剂的实例包括软骨素B类似物。 已经显示某些癌症对软骨素B类似物的易感性与特定的微管蛋白同种型或其它微管相关蛋白如MAP-4和stathmin的表达相关。 诸如这些的相关性可以用于鉴定适合于使用特定化学治疗剂的治疗的患者。 这样的系统避免了治疗患有细胞毒性化合物的患者，其中对癌症最小或没有影响。 本发明还提供了一种为不同化合物和癌症类型建立这些相关性的系统。 该系统将特别有用于建立抗微管剂和肺癌，乳腺癌和卵巢癌等癌症之间的相关性。 还提供了可用于实践本发明的试剂盒和试剂。

    Tubulin isotype screening in cancer therapy using hemiasterlin analogs
    10.
    发明申请
    Tubulin isotype screening in cancer therapy using hemiasterlin analogs 审中-公开
    使用半球蛋白类似物的癌症治疗中的微管蛋白同种型筛选

    公开(公告)号：US20060148014A1

    公开(公告)日：2006-07-06

    申请号：US11296920

    申请日：2005-12-07

    Applicant: Sergei Agoulnik ,  Galina Kuznetsov ,  Bruce Littlefield

    Inventor： Sergei Agoulnik ,  Galina Kuznetsov ,  Bruce Littlefield

    IPC: G01N33/574 ,  A61K31/44 ,  A61K31/18 ,  A61K38/04

    CPC classification number: G01N33/57415 ,  A61K9/06 ,  A61K31/18 ,  A61K31/44 ,  A61K38/04 ,  G01N33/574 ,  G01N33/57423 ,  G01N33/57449 ,  G01N2333/4703 ,  G01N2800/44

    Abstract: Chemotherapeutic agents that interfere with microtubule assembly or disassembly in the cell are potent inhibitors of cell replication. Examples of such agents include hemiasterlin analogs. It has been shown that the susceptibility of certain cancers to analogs of hemiasterlin correlates with the expression of particular tubulin isotypes or other microtubule-associated proteins such as MAP-4 and stathmin. Correlations such as these may be used in identifying patients suitable for treatment using a particular chemotherapeutic agent. Such a system avoids treating patients with cytotoxic compounds where there is a minimal or no effect on the cancer. The invention also provides a system of establishing these correlations for different compounds and cancer types. The system will be particularly useful in establishing correlations between anti-microtubule agents and cancers such as lung, breast, and ovarian cancer. Kits and reagents useful in practicing the invention are also provided.

    Abstract translation: 影响细胞中微管组装或分解的化学治疗剂是细胞复制的有效抑制剂。 这些药剂的实例包括半球蛋白类似物。 已经表明，某些癌症对半细胞因子类似物的易感性与特定的微管蛋白同种型或其它微管相关蛋白如MAP-4和stathmin的表达相关。 诸如这些的相关性可以用于鉴定适合于使用特定化学治疗剂的治疗的患者。 这样的系统避免了治疗患有细胞毒性化合物的患者，其中对癌症最小或没有影响。 本发明还提供了一种为不同化合物和癌症类型建立这些相关性的系统。 该系统将特别有用于建立抗微管剂和肺癌，乳腺癌和卵巢癌等癌症之间的相关性。 还提供了可用于实践本发明的试剂盒和试剂。

Patent Agency Ranking